Literature DB >> 16799336

Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity.

Constanze Voigtländer1, Susanne Rössner, Eva Cierpka, Gabi Theiner, Carsten Wiethe, Mauritius Menges, Gerold Schuler, Manfred B Lutz.   

Abstract

Dendritic cell (DC) maturation can occur by different types of stimuli. Previously, we described that murine DC matured with tumor necrosis factor (TNF) up-regulate surface MHC and costimulatory molecules but lack cytokine release, and therefore termed them semi-mature DC. These TNF/DC-induced tolerance after intravenous (i.v.) injection in a model of experimental autoimmune encephalomyelitis (EAE). Here, we show that TNF/DC are not terminally differentiated but can still respond to the microbial stimulus lipopolysaccharide. Subcutaneously injected TNF/DC induce an unpolarized T(H)1/T(H)2 response and are not protective in the experimental autoimmune encephalomyelitis model. Although TNF/DC home to the draining lymph node, they remain negative for intracellular cytokine stainings. However, the nonmigrating, endogenous DC started to produce interleukin (IL)-12p40, TNF and little IL-6, IL-10, and MCP-1 in a bystander fashion. Together, DC matured with the inflammatory stimulus TNF remains responsive to further signals in vitro and in vivo. These signals can be provided by pathogens or the subcutaneous injection route, which can convert them from tolerogenic to immunogenic DC. These findings are important for selecting the appropriate injection route of human DC for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799336     DOI: 10.1097/01.cji.0000210081.60178.b4

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  35 in total

1.  Multi-compartmental vaccine delivery system for enhanced immune response to gp100 peptide antigen in melanoma immunotherapy.

Authors:  Mayurkumar Kalariya; Srinivas Ganta; Mansoor Amiji
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

2.  Activated apoptotic cells induce dendritic cell maturation via engagement of Toll-like receptor 4 (TLR4), dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN), and β2 integrins.

Authors:  Sushil Kumar Pathak; Annette E Sköld; Venkatramanan Mohanram; Catrine Persson; Ulrika Johansson; Anna-Lena Spetz
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

3.  The effect of cyclic mechanical strain on activation of dendritic cells cultured on adhesive substrates.

Authors:  Jamal S Lewis; Natalia V Dolgova; Thomas J Chancellor; Abhinav P Acharya; Jerome V Karpiak; Tanmay P Lele; Benjamin G Keselowsky
Journal:  Biomaterials       Date:  2013-09-03       Impact factor: 12.479

4.  Immunotherapy using lipopolysaccharide-stimulated bone marrow-derived dendritic cells to treat experimental autoimmune encephalomyelitis.

Authors:  F Zhou; B Ciric; G-X Zhang; A Rostami
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

5.  Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro.

Authors:  Sung Hee Yoon; Sun Ok Yun; Jung Yong Park; Hee Yeun Won; Eun Kyung Kim; Hyun Jung Sohn; Hyun Il Cho; Tai Gyu Kim
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

6.  TNF-alpha-treated DC exacerbates disease in a murine tumor metastasis model.

Authors:  Nasreen Vohra; Monique Verhaegen; Lisa Martin; Amy Mackay; Shari Pilon-Thomas
Journal:  Cancer Immunol Immunother       Date:  2010-05       Impact factor: 6.968

7.  Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype.

Authors:  Javiera Obreque; Fabián Vega; Andy Torres; Loreto Cuitino; Juan P Mackern-Oberti; Paola Viviani; Alexis Kalergis; Carolina Llanos
Journal:  Immunology       Date:  2017-08-23       Impact factor: 7.397

Review 8.  Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.

Authors:  M J Mansilla; S Presas-Rodríguez; A Teniente-Serra; I González-Larreategui; B Quirant-Sánchez; F Fondelli; N Djedovic; D Iwaszkiewicz-Grześ; K Chwojnicki; Đ Miljković; P Trzonkowski; C Ramo-Tello; E M Martínez-Cáceres
Journal:  Cell Mol Immunol       Date:  2021-05-06       Impact factor: 22.096

Review 9.  Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

Authors:  C M U Hilkens; J D Isaacs
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

10.  Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis.

Authors:  Denize Atan; Jarka Heissigerova; Lucia Kuffová; Aideen Hogan; Dara J Kilmartin; John V Forrester; Jeff L Bidwell; Andrew D Dick; Amanda J Churchill
Journal:  Mol Vis       Date:  2013-01-28       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.